<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22963">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02807844</url>
  </required_header>
  <id_info>
    <org_study_id>CMCS110Z2102</org_study_id>
    <secondary_id>2016-000210-29</secondary_id>
    <nct_id>NCT02807844</nct_id>
  </id_info>
  <brief_title>Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies</brief_title>
  <official_title>A Phase Ib/II, Open Label, Multicenter Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study of MCS110 with PDR001 is to characterize the safety, tolerability,
      pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of
      MCS110 with PDR001 in adult patients with solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2016</start_date>
  <completion_date type="Anticipated">June 17, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 29, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(phase 1) Number of patients with adverse events, as a measure of safety</measure>
    <time_frame>two cycles of treatment; cycle = 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(phase 2) : Overall Response rate (ORR)</measure>
    <time_frame>6 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Overall Response Rate (ORR)</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: progression free survival (PFS)</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Overall response rate per immune related Response Criteria</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 : clinical benefit rate (CBR)</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 : duration of response (DOR)</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 : disease control rate (DCR)</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 : Progression Free Survival (PFS)</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Duration Of Response (DOR)</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 : Disease Control Rate (DCR)</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 : Clinical Benefit Rate (CBR)</measure>
    <time_frame>6 months of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">95</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Pancreatic Carcinoma</condition>
  <condition>Melanoma</condition>
  <condition>Endometrial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Pancreatic cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple Negative Breast cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Endometrial Carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Melanoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCS110</intervention_name>
    <arm_group_label>Pancreatic cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast cancer</arm_group_label>
    <arm_group_label>Endometrial Carcinoma</arm_group_label>
    <arm_group_label>Melanoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <arm_group_label>Pancreatic cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast cancer</arm_group_label>
    <arm_group_label>Endometrial Carcinoma</arm_group_label>
    <arm_group_label>Melanoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent prior to any procedures

          -  Patients with advanced melanoma, endometrial carcinoma, pancreatic or TNBC, with
             measurable or non-measurable disease who have progressed despite standard therapy or
             are intolerant of standard therapy, or for whom no standard therapy exists.

        Exclusion Criteria:

          -  Patient having out of range laboratory values defined as:

          -  Creatinine clearance &lt; 40 mL/min

          -  Total bilirubin &gt; 1.5 x ULN

          -  Absolute neutrophil count &lt; 1.0 x 109/L

          -  Hemoglobin (Hgb) &lt; 9 g/dL

          -  Impaired cardiac function or clinically significant cardiac disease

          -  Active autoimmune disease

          -  Malignant disease, other than that being treated in this study.

          -  Presence of â‰¥ CTCAE Grade 2 toxicity due to prior cancer therapy.

          -  Pregnant or lactating women

        Other protocol-defined inclusion/exclusion may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lacey McQuinn</last_name>
      <phone>713-792-0007</phone>
      <email>lmcquinn@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Aung Naing</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>HUS</city>
        <zip>FIN-00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 27, 2017</lastchanged_date>
  <firstreceived_date>June 17, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Triple negative breast cancer</keyword>
  <keyword>Pancreatic carcinoma</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Endometrial Carcinoma</keyword>
  <keyword>Immuno oncology</keyword>
  <keyword>Monoclonal antibody</keyword>
  <keyword>PDR001</keyword>
  <keyword>MCS110</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
